市售肠用空硬胶囊、生产技术及应用。

Aleš Franc, David Vetchý, Nicole Fülöpová
{"title":"市售肠用空硬胶囊、生产技术及应用。","authors":"Aleš Franc,&nbsp;David Vetchý,&nbsp;Nicole Fülöpová","doi":"10.3390/ph15111398","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, there is a growing need to prepare small batches of enteric capsules for individual therapy or clinical evaluation since many acidic-sensitive substances should be protected from the stomach's acidic environment, including probiotics or fecal material, in the fecal microbiota transplantation (FMT) process. A suitable method seems to be the encapsulation of drugs or lyophilized alternatively frozen biological suspensions in commercial hard enteric capsules prepared by so-called Enteric Capsule Drug Delivery Technology (ECDDT). Manufacturers supply these types of capsules, made from pH-soluble polymers, in products such as AR Caps<sup>®</sup>, EnTRinsic<sup>TM</sup>, and Vcaps<sup>®</sup> Enteric, or capsules made of gelling polymers that release their content as the gel erodes over time when passing through the digestive tract. These include DRcaps<sup>®</sup>, EMBO CAPS<sup>®</sup> AP, BioVXR<sup>®</sup>, or ACGcaps™ HD. Although not all capsules in all formulations meet pharmaceutical requirements for delayed-release dosage forms in disintegration and dissolution tests, they usually find practical application. This literature review presents their composition and properties. Since ECDDT is a new technology, this article is based on a limited number of references.</p>","PeriodicalId":520747,"journal":{"name":"Pharmaceuticals (Basel, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696354/pdf/","citationCount":"6","resultStr":"{\"title\":\"Commercially Available Enteric Empty Hard Capsules, Production Technology and Application.\",\"authors\":\"Aleš Franc,&nbsp;David Vetchý,&nbsp;Nicole Fülöpová\",\"doi\":\"10.3390/ph15111398\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Currently, there is a growing need to prepare small batches of enteric capsules for individual therapy or clinical evaluation since many acidic-sensitive substances should be protected from the stomach's acidic environment, including probiotics or fecal material, in the fecal microbiota transplantation (FMT) process. A suitable method seems to be the encapsulation of drugs or lyophilized alternatively frozen biological suspensions in commercial hard enteric capsules prepared by so-called Enteric Capsule Drug Delivery Technology (ECDDT). Manufacturers supply these types of capsules, made from pH-soluble polymers, in products such as AR Caps<sup>®</sup>, EnTRinsic<sup>TM</sup>, and Vcaps<sup>®</sup> Enteric, or capsules made of gelling polymers that release their content as the gel erodes over time when passing through the digestive tract. These include DRcaps<sup>®</sup>, EMBO CAPS<sup>®</sup> AP, BioVXR<sup>®</sup>, or ACGcaps™ HD. Although not all capsules in all formulations meet pharmaceutical requirements for delayed-release dosage forms in disintegration and dissolution tests, they usually find practical application. This literature review presents their composition and properties. Since ECDDT is a new technology, this article is based on a limited number of references.</p>\",\"PeriodicalId\":520747,\"journal\":{\"name\":\"Pharmaceuticals (Basel, Switzerland)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696354/pdf/\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals (Basel, Switzerland)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/ph15111398\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals (Basel, Switzerland)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph15111398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

目前,由于在粪便微生物群移植(FMT)过程中需要保护许多酸敏感物质(包括益生菌或粪便物质)不受胃酸性环境的影响,因此越来越需要制备小批量肠胶囊用于个体治疗或临床评估。一种合适的方法似乎是将药物或冻干或冷冻的生物悬浮液包封在所谓的肠胶囊给药技术(ECDDT)制备的商业硬肠胶囊中。制造商提供这些类型的胶囊,由ph溶性聚合物制成,用于AR Caps®,EnTRinsicTM和Vcaps®Enteric等产品,或由凝胶聚合物制成的胶囊,凝胶在通过消化道时随着时间的推移而被侵蚀,释放出其内容物。这些包括DRcaps®,EMBO CAPS®AP, BioVXR®或ACGcaps™HD。虽然在崩解和溶出试验中,并非所有制剂中的所有胶囊都符合缓释剂型的药学要求,但它们通常都有实际应用。本文综述了它们的组成和性质。由于ECDDT是一项新技术,本文仅基于有限的参考文献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Commercially Available Enteric Empty Hard Capsules, Production Technology and Application.

Commercially Available Enteric Empty Hard Capsules, Production Technology and Application.

Commercially Available Enteric Empty Hard Capsules, Production Technology and Application.

Commercially Available Enteric Empty Hard Capsules, Production Technology and Application.

Currently, there is a growing need to prepare small batches of enteric capsules for individual therapy or clinical evaluation since many acidic-sensitive substances should be protected from the stomach's acidic environment, including probiotics or fecal material, in the fecal microbiota transplantation (FMT) process. A suitable method seems to be the encapsulation of drugs or lyophilized alternatively frozen biological suspensions in commercial hard enteric capsules prepared by so-called Enteric Capsule Drug Delivery Technology (ECDDT). Manufacturers supply these types of capsules, made from pH-soluble polymers, in products such as AR Caps®, EnTRinsicTM, and Vcaps® Enteric, or capsules made of gelling polymers that release their content as the gel erodes over time when passing through the digestive tract. These include DRcaps®, EMBO CAPS® AP, BioVXR®, or ACGcaps™ HD. Although not all capsules in all formulations meet pharmaceutical requirements for delayed-release dosage forms in disintegration and dissolution tests, they usually find practical application. This literature review presents their composition and properties. Since ECDDT is a new technology, this article is based on a limited number of references.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信